Astrana Health, Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +20.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.31 | $0.40 | +29.0% | Beat | |
| Q1 FY26 | not reported | $0.74 | not reported | not reported | |
| Q4 FY25 | not reported | $0.54 | not reported | not reported | Q4 FY25 call |
| Q3 FY25 | not reported | $0.01 | not reported | not reported | |
| Q2 FY25 | $0.36 | $0.19 | -47.2% | Miss | |
| Q1 FY25 | $0.23 | $0.14 | -39.1% | Miss | |
| Q4 FY24 | not reported | $-0.15 | not reported | not reported | |
| Q3 FY24 | $0.33 | $0.33 | +0.0% | Beat | |
| Q2 FY24 | $0.38 | $0.40 | +5.3% | Beat | |
| Q1 FY24 | $0.32 | $0.31 | -3.1% | Miss | |
| Q4 FY23 | $0.17 | $0.26 | +52.9% | Beat | |
| Q3 FY23 | $0.27 | $0.47 | +74.1% | Beat |
Back to ASTH overview · ASTH holders · ASTH KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.